SHANGHAI, June 21 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Wei-Min Chang has been appointed Vice President of Operations and General Manager of the company's SynTheAll (STA) manufacturing facility, located in the Jinshan chemical industry zone of Shanghai. Mr. Chang will report to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
Dr. Eric Gu, former Vice President of Operations and General Manager of STA, has been appointed Vice President of Business Development for Manufacturing Services, reporting to Dr. Suhan Tang, Chief Manufacturing Officer.
The Company's SynTheAll facility manufactures active pharmaceutical ingredients (APIs) and advanced intermediates for our customers' use in preclinical and clinical trials. The company recently completed construction of an expanded facility, known as SynTheAll Phase 2, to produce advanced intermediates and APIs for late-stage clinical trials and commercial supplies. This new facility is expected to open in stages, beginning in late 2009.
Prior to joining WuXi, Mr. Chang worked at Eastbound Synopharma (HK)
Holding Co. as Vice President of Chemical Development, responsible for
research and development, small-scale manufacturing, quality control/quality
assurance, regulatory affairs and other general administrative functions at
Eastbound Shanghai Institute. From 1999 to 2006, he worked for Taiwan Biotech
as the company's head of U.S. operations and as Vice President of
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved